Business Description
Cambium Bio Ltd
ISIN : AU0000327769
Description
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.87 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | -0.12 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 46.9 | |||||
3-Year EPS without NRI Growth Rate | 46.9 | |||||
3-Year FCF Growth Rate | 37.5 | |||||
3-Year Book Growth Rate | -34.2 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 32.29 | |||||
9-Day RSI | 41.43 | |||||
14-Day RSI | 45.26 | |||||
3-1 Month Momentum % | -22.92 | |||||
6-1 Month Momentum % | -21.28 | |||||
12-1 Month Momentum % | 76.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.13 | |||||
Quick Ratio | 2.13 | |||||
Cash Ratio | 1.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -81.4 | |||||
Shareholder Yield % | -33.96 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -175.71 | |||||
ROA % | -102.59 | |||||
ROIC % | -152.14 | |||||
ROC (Joel Greenblatt) % | -71360 | |||||
ROCE % | -149.62 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.67 | |||||
Price-to-Tangible-Book | 41.5 | |||||
EV-to-EBIT | -3.08 | |||||
EV-to-EBITDA | -3.08 | |||||
EV-to-Forward-EBITDA | 8.95 | |||||
EV-to-Forward-Revenue | 13.33 | |||||
EV-to-FCF | -3.24 | |||||
| Price-to-Net-Current-Asset-Value | 41.5 | |||||
Earnings Yield (Greenblatt) % | -32.47 | |||||
FCF Yield % | -34.4 |
GF Valueâ„¢
Cambium Bio Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cambium Bio Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.01:1 Stock Split | 2024-07-04 | 0.40 (+0.00%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Cambium Bio Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers